6-fluoro-4-methyl-1H-indole | 885521-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-fluoro-4-methyl-1H-indole
• CAS: 885521-06-2
• 化学式: C₉H₈FN
• mdl: MFCD07781479
• 分子量: 149.168
• InChiKey: FBQSMVHWHHQNAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-fluoro-4-methyl-1H-indole 在 盐酸 、 碘苯二乙酸 、 水 、 溶剂黄146 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 42.0h， 生成 1-[4-[benzenesulfonyl(methyl)amino]phenyl]-7-fluoro-5-methyl-9H-pyrido[3,4-b]indole-3-carboxylic acid
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE
  [FR] INHIBITEURS À PETITES MOLÉCULES DE L'UBIQUITINE LIGASE CRL4

  摘要：

  Compounds of formula (I), compounds of formula (II), and compounds of formula (III) are disclosed. Also disclosed are compounds, compositions, and methods to inhibit CUL4A expression or activity, CUL4B expression or activity, and/or DDB1 expression or activity for the treatment or prevention of cancer, DNA damage, or related conditions. In some aspects, the interaction between CUL4A and/or CUL4B and the beta-propeller B of DDB1 is disrupted with the compounds, compositions, or methods.

  公开号：

  WO2023173136A2
• 作为产物：
  描述：

  (E)-2-(2-bromo-4-fluoro-6-nitrophenyl)-N,N-dimethylethenamine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 铁粉 、 potassium carbonate 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 14.0h， 生成 6-fluoro-4-methyl-1H-indole
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE
  [FR] INHIBITEURS À PETITES MOLÉCULES DE L'UBIQUITINE LIGASE CRL4

  摘要：

  Compounds of formula (I), compounds of formula (II), and compounds of formula (III) are disclosed. Also disclosed are compounds, compositions, and methods to inhibit CUL4A expression or activity, CUL4B expression or activity, and/or DDB1 expression or activity for the treatment or prevention of cancer, DNA damage, or related conditions. In some aspects, the interaction between CUL4A and/or CUL4B and the beta-propeller B of DDB1 is disrupted with the compounds, compositions, or methods.

  公开号：

  WO2023173136A2

文献信息

• [EN] BENZOTHIADIAZINE COMPOUNDS<br/>[FR] COMPOSÉS BENZOTHIADIAZINE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017098421A1

  公开（公告）日：2017-06-15

  The invention is directed to substituted benzothiadiazine derivatives. Specifically, the invention is directed to compounds according to Formula (I):wherein R, R1, R2, R3, R4 and R5 are as defined herein. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代苯并噻二嗪衍生物。具体而言，本发明涉及式(I)化合物：其中R、R1、R2、R3、R4和R5定义如下。本发明的化合物是CD73的抑制剂，可用于治疗癌症、前癌综合症和与CD73抑制相关的疾病，如艾滋病、自身免疫病、感染、动脉粥样硬化和缺血-再灌注损伤。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明更进一步的涉及使用本发明化合物或包含本发明化合物的药物组合物抑制CD73活性和治疗相关疾病的方法。
• [EN] 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISEASES OR CANCER<br/>[FR] DÉRIVÉS 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE QUI SONT UTILES POUR LE TRAITEMENT DE MALADIES IMMUNITAIRES OU INFLAMMATOIRES OU DU CANCER
  申请人：CELON PHARMA SA

  公开号：WO2016157091A1

  公开（公告）日：2016-10-06

  A compound of the general formula (I) wherein Y represents -CH2- or >C=0; R1 is selected from the group consisting of A1, A2 and A3; R2 represents dioxothiomorpholino moiety B1, piperazinyl moiety B2, azetidinyl moiety B3, or piperidinyl moiety B4; R3 is selected from the group consisting of H, halogen, and C1 -C4 alkyl; R4 is selected from the group consisting of C1 -C4 alkyl, C3-C4- cycloalkyl, C1 -C4 alkyl substituted with C1 -C4 alkoxy, and CHF2, and their pharmaceutically acceptable salts. Pharmaceutical compositions comprising said compounds and their use in the treatment of diseases of immune system, inflammatory diseases and cancer.

  通用式（I）的化合物，其中Y代表-CH2-或>C=0；R1从A1、A2和A3组成的群体中选择；R2代表二氧硫吗啉基团B1、哌嗪基团B2、氮杂环丁基团B3或哌啶基团B4；R3从H、卤素和C1-C4烷基组成的群体中选择；R4从C1-C4烷基、C3-C4环烷基、C1-C4烷基取代的C1-C4烷氧基和CHF2组成的群体中选择，以及它们的药学上可接受的盐。包括所述化合物的药物组合物及其在治疗免疫系统疾病、炎症性疾病和癌症中的用途。
• NOVEL P2X7R ANTAGONISTS AND THEIR USE
  申请人：Bös Michael

  公开号：US20090312366A1

  公开（公告）日：2009-12-17

  The present application is directed to novel P2X7R antagonists that are indol-3-carboxamide or azaindole-3-carboxamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.

  本申请涉及新型P2X7R拮抗剂，其为吲哚-3-羧酰胺或氮杂吲哚-3-羧酰胺化合物，包括这些化合物的药物组合物，以及它们用于预防或治疗由P2X7R活性介导的疾病。
• CHEMICAL COMPOUNDS 610
  申请人：Foote Kevin Michael

  公开号：US20110053923A1

  公开（公告）日：2011-03-03

  There is provided pyrimidinyl indole compounds of Formula (I), or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  提供了式(I)的嘧啶基吲哚化合物或其药学上可接受的盐，其制备过程，包含它们的制药组合物以及它们在治疗中的使用。
• [EN] QUINOXALINONE DERIVATIVE AS IRREVERSIBLE INHIBITOR OF KRAS G12C MUTANT PROTEIN<br/>[FR] DÉRIVÉ DE QUINOXALINONE EN TANT QU'INHIBITEUR IRRÉVERSIBLE DE LA PROTÉINE MUTANTE KRAS G12C<br/>[ZH] 喹喔啉酮衍生物作为KRAS G12C突变蛋白的不可逆抑制剂
  申请人：BEIJING TIDE PHARMACEUTICAL CO LTD

  公开号：WO2021219091A2

  公开（公告）日：2021-11-04

  本发明涉及新的喹喔啉酮衍生物，其可作为KRAS G12C突变蛋白的不可逆抑制剂。本发明还涉及含有该喹喔啉酮衍生物的药物组合物，及其制备方法和用途。